ROBERTSON, STEPHENS MEDICAL CONFERENCE HIGHLIGHTS: Agouron Pharmaceuticals' AG-337
Executive Summary
Agouron Pharmaceuticals' AG-337: Anti-cancer drug for solid tumors, tradenamed Thymitaq, shows positive trends in six Phase II trials, La Jolla-based firm reports. Of 78 evaluable patients to date with solid malignant tumors, four of 14 with head/neck cancer have greater than 50% reductions in all measurable disease; one of 13 patients with primary liver cancer had a 70% reduction in measurable disease; 10 of 14 pancreatic cancer patients experienced stable disease; and 32 of 37 patients with lung, prostate or colon cancer had stabilized the cancer. Myelosuppression of short duration and mouth sores were the primary toxicities found in the studies. Agouron is finalizing plans to study the thymidylate synthase inhibitor further in head/neck cancer and primary liver cancer...